Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Innovative Drug Availability Remains Low Across Chinese Hospitals Despite National Reimbursement Listing

1 day ago 10

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

A national cross-sectional evaluation of China’s National Reimbursement Drug List has revealed that the hospital availability of negotiated innovative medications remains substantially constrained across the country. Researchers assessed the presence of these covered therapies across healthcare facilities and established that overall procurement rates were low despite nationwide pricing agreements. The findings demonstrate marked institutional variation, showing that tertiary hospitals maintain significantly broader access to these innovative pharmaceuticals than secondary facilities.

According to the quantitative assessment, the average availability rate of listed innovative drugs reached 12.09 percent with a standard deviation of 12.46 percent within tertiary medical institutions. In sharp contrast, secondary healthcare facilities recorded an average availability rate of only 2.25 percent with a standard deviation of 3.49 percent. This pronounced divergence indicates that patient access to newly negotiated innovative treatments remains heavily concentrated in higher-tier medical centers across Chinese provinces.

Geographic disparities were also prominent across different regions of China, with the East region securing the highest relative availability across hospital categories. Within the East, tertiary institutions registered an availability rate of 14.16 percent with a standard deviation of 13.87 percent, while secondary hospitals achieved 3.13 percent with a standard deviation of 4.02 percent. Conversely, healthcare facilities situated in the Western and Northeastern regions demonstrated comparatively lower rates of drug availability, underscoring pronounced geographic imbalances in medication distribution.

Substantial variation was similarly documented among tertiary hospitals across individual administrative divisions. Tertiary centers located in Shanghai exhibited the highest availability at 20.62 percent with a standard deviation of 19.24 percent, closely followed by facilities in Xinjiang at 18.05 percent with a standard deviation of 16.83 percent, and Anhui at 17.23 percent with a standard deviation of 18.90 percent. Conversely, tertiary institutions located in Sichuan demonstrated an average availability of 8.94 percent with a standard deviation of 6.23 percent, Hubei recorded 10.12 percent with a standard deviation of 7.14 percent, and Shandong reached 12.17 percent with a standard deviation of 10.57 percent.

To rigorously evaluate the distribution dynamics, the research team constructed a healthcare resource index S as their core analytical unit, employing a dual-weighting strategy based on regional population and existing healthcare facilities. The evaluation utilized standard World Health Organization and Health Action International methodologies to benchmark drug availability across sampled facilities, allowing the authors to systematically evaluate multidimensional regional distribution patterns.

Equity assessments carried out using the Gini coefficient reflected better structural equity across tertiary healthcare facilities, generating coefficient values between 0.1 and 0.3, compared to secondary facilities, which produced Gini values between 0.2 and 0.4. Furthermore, an equity decomposition using the Theil index revealed that intraregional disparities served as the primary contributor to overall systemic inequity, with both the Eastern and Western zones experiencing the highest internal disparities in medication availability.

The study authors concluded that secondary healthcare facilities located in China’s Western and Northeastern regions confront the most severe hurdles regarding innovative pharmaceutical access. To mitigate these disparities, the researchers highlighted the necessity of structural policy interventions, including establishing standardized timelines for hospital drug admission, enhancing medical insurance funding support, and refining hospital evaluation metrics to bolster drug inclusion in provincial secondary hospitals.

Ensuring equitable access to innovative drugs remains crucial for public health, yet national reimbursement listing alone does not eliminate regional and institutional disparities. Even after inclusion on China’s National Reimbursement Drug List, substantial availability gaps persist between tertiary and secondary facilities. This divide demonstrates that central coverage decisions must be matched by targeted local support to ensure innovative therapies reach patients across all hospital tiers.

The application of the Theil index highlights that regional differences represent the primary driver of overall inequality. Because intraregional disparities within both the East and West regions contribute heavily to this imbalance, policy interventions must address localized divides. Supporting secondary healthcare facilities through standardized admission procedures and adequate insurance funding remains vital for achieving balanced nationwide access.

Subject of Research: Availability and equity of National Reimbursement Drug List-negotiated innovative drugs in Chinese hospitals

Article Title: Availability and equity analysis of China’s National Reimbursement Drug List-negotiated drugs: a national cross-sectional analysis

Article References: Liu, Y., Lin, X., Hu, J., & Li, F. (2026). Availability and equity analysis of China’s National Reimbursement Drug List-negotiated drugs: a national cross-sectional analysis. Health Economics Review. https://doi.org/10.1186/s13561-026-00844-7

Image Credits: AI Generated

DOI: 10.1186/s13561-026-00844-7

Keywords: National Reimbursement Drug List, China healthcare, innovative drugs, drug availability, healthcare equity, tertiary hospitals, secondary hospitals, health economics, Gini coefficient, Theil index, pharmaceutical policy, WHO-HAI methodology, regional disparities, hospital procurement, medical insurance

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway